August 13, 2024
Biora Therapeutics Announces Funding Agreement with Existing Investors
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnershipSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE)…
Pharmaceuticals, Biotechnology and Life Sciences
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnershipSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE)…
Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate…
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024,…
BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today…
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology…
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1…
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential…
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…
TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract…
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across…